Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2

Blood

Volumn 112, Issue 5, 2008, Pages 1931-1941

  Arendt, Bonnie K ^a   Ramirez Alvarado, Marina ^b   Sikkink, Laura A ^b   Keats, Jonathan J ^c   Ahmann, Gregory J ^c   Dispenzieri, Angela ^d   Fonseca, Rafael ^c   Ketterling, Rhett P ^d   Knudson, Ryan A ^d   Mulvihill, Erin M ^a   Tschumper, Renee C ^a   Wu, Xiaosheng ^a   Zeldenrust, Steven R ^d   Jelinek, Diane F ^a,b  

^a Department of Immunology ^*  (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; AMYLOID; CYTOKINE; IMMUNOGLOBULIN LAMBDA CHAIN; PRIMER DNA;

ADULT; AMYLOIDOSIS; ARTICLE; CASE REPORT; CELL LINE; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; AMINO ACID SEQUENCE; BIOSYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; CHROMOSOME ABERRATION; DNA MICROARRAY; DRUG EFFECT; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; IMMUNOGLOBULIN GENE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

AMINO ACID SEQUENCE; AMYLOID; AMYLOIDOSIS; BASE SEQUENCE; CELL LINE; CHROMOSOME ABERRATIONS; CYTOKINES; DNA PRIMERS; FEMALE; GENES, IMMUNOGLOBULIN; HUMANS; IMMUNOGLOBULIN LAMBDA-CHAINS; IN SITU HYBRIDIZATION, FLUORESCENCE; MICROSCOPY, ELECTRON, TRANSMISSION; MIDDLE AGED; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMA CELLS; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 52649129150     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-143040     Document Type: Article

References (66)

1. Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis: recognition, confirmation, prognosis, and therapy. Mayo Clin Proc. 1999;74:490-494.
2. Perfetti V, Casarini S, Palladini G, et al. Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdalll) as a new amyloid-associated germline gene segment. Blood. 2002:100:948-953.
3. Bellotti V, Mangione P. Merlini G. Review: immunoglobulin light chain amyloidosis-the archetype of structural and pathogenic variability. J Struct Biol. 2000;130:280-289.
4. Sipe JD. Amyloidosis. Annu Rev Biochem. 1992: 61:947-975.
5. Stevens FJ, Kisilevsky R. Immunoglobulin light chains, glycosaminoglycans, and amyloid. Cell Mol Life Sci. 2000;57:441-449.
6. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc. 2006;81:693-703.
7. Hrncic R, Wall J, Wolfenbarger DA, et al. Antibody-mediated resolution of light chainassociated amyloid deposits. Am J Pathol. 2000; 157:1239-1246.
8. Koss MN, Pirani CL, Osserman EF. Experimental Bence Jones cast nephropathy. Lab Invest. 1976; 34:579-591.
9. Solomon A, Weiss DT, Pepys MB. Induction in mice of human light-chain-associated amyloidosis. Am J Pathol. 1992;140:629-637.
10. Stevens PW, Raffen R, Hanson DK, et al. Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light-chain amyloid proteins. Protein Sci. 1995;4:421-432.
11. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004;94:1008-1010.
12. Keeling J, Teng J, Herrera GA. AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest. 2004;84: 1322-1338.
13. Monis GF, Schultz C, Ren R, et al. Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts. Am J Pathol. 2006;169:1939-1952.
14. Teng J, Russell WJ, Gu X, Cardelli J, Jones ML, Herrera GA. Different types of glomerulopathy light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest. 2004;84:440-451.
15. Trinkaus-Randall V, Walsh MT, Steeves S, Monis G, Connors LH, Skinner M. Cellular response of cardiac fibroblasts to amyloidogenic light chains. Am J Pathol. 2005;166:197-208.
16. Jelinek DF, Tschumper RC, Geyer SM, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol. 2001;115:854-861.
17. Lefranc MP. IMGT, the international ImMuno-GeneTics database. Nucleic Acids Res. 2001;29: 207-209. (http://imgt.cines.fr/IMGT-rquest/share/textes/.) Accessed January 2008.
18. Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA, Jelinek DF. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia. 1996;10:866-876.
19. Ahmann GJ, Jalal SM, Juneau AL, et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet. 1998;101: 7-11.
20. Hamilton MS, Ball J, Bromidge E, Lowe J, Franklin IM. Characterization of new IgG lambda myeloma plasma cell line (EJM): a further tool in the investigation of the biology of multiple myeloma. Br J Haematol. 1990;75:378-384.
21. Jelinek DF, Ahmann GJ, Greipp PR, et al. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res. 1993;53:5320-5327.
22. Ohbayashi K, Taniwaki M, Ninomiya M, et al. A xeno-transplantable plasma cell leukemia line with a split translocation of the IgH gene. Cancer Genet Cytogenet. 2003;144:31-35.
23. Sikkink LA, Ramirez-Alvarado M. Biochemical and aggregation analysis of Bence Jones proteins from different light chain diseases. Amyloid. 2008;15:29-39.
24. Pokkuluri PR, Solomon A, Weiss DT, Stevens FJ, Schiffer M. Tertiary structure of human lambda 6 light chains. Amyloid. 1999;6:165-171.
25. Drew M, Barker HF, Ball J, Pearson C, Cook G, Franklin I. Very late antigen (VLA) expression by normal and neoplastic human plasma cells; including an assessment of antibodies submitted to the Vth International Workshop on Leucocyte Differentiation Antigens using human myeloma cell lines. Leuk Res. 1996;20:619-624.
26. Medina F, Segundo C, Jimenez-Gomez G, Gonzalez-Garcia I, Campos-Caro A, Brieva JA. Higher maturity and connective tissue association distinguish resident from recently generated human tonsil plasma cells. J Leukoc Biol. 2007;82: 1430-1436.
27. Otsuyama K, Asaoku H, Kawano MM. An increase in MPC-1-and MPC-1-CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis: the revised phenotypic classification of monoclonal marrow plasmacytosis (MOMP-2005). Int J Hematol. 2006;83:39-43.
28. Orentas RJ. Determination of Epstein-Barr virus (EBV) load by RT-PCR and cellular dilution. Mol Cell Probes. 1998;12:427-430.
29. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23:6333-6338.
30. Tonon G. Molecular pathogenesis of multiple myeloma. Hematol Oncol Clin North Am. 2007;21: 985-1006.
31. Ocio EM, Schop RF, Gonzalez B, et al. 6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis. Br J Haematol. 2007;136:80-86.
32. Hayashibara T Yamada Y, Mori N, et al. Possible involvement of aryl hydrocarbon receptor (AhR) in adult T-cell leukemia (ATL) leukemogenesis: constitutive activation of AhR in ATL. Biochem Biophys Res Commun. 2003;300:128-134.
33. Wuilleme-Toumi S, Robillard N, Gomez P, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia. 2005;19:1248-1252.
34. Cummins JM, He Y, Leary RJ, et al. The colorectal microRNAome. Proc Natl Acad Sci U S A. 2006;103:3687-3692.
35. Dale BA, Resing KA, Lonsdale-Eccles JD. Filaggrin: a keratin filament associated protein. Ann N YAcad Sci. 1985;455:330-342.
36. Steinert PM, Cantieri JS, Teller DC, Lonsdale-Eccles JD, Dale BA. Characterization of a class of cationic proteins that specifically interact with intermediate filaments. Proc Natl Acad Sci U S A. 1981;78:4097-4101.
37. Bergink S, Salomons FA, Hoogstraten D, et al. DNA damage triggers nucleotide excision repairdependent monoubiquitylation of histone H2A. Genes Dev. 2006;20:1343-1352.
38. Oguri T, Achiwa H, Sato S, et al. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther. 2006;5:1800-1806.
39. Schultheis PJ, Hagen TT, O'Toole KK, et al. Characterization of the P5 subfamily of P-type transport ATPases in mice. Biochem Biophys Res Commun. 2004;323:731-738.
40. Rodriguez V, Chen Y, Elkahloun A, Dutra A, Pak E. Chandrasekharappa S. Chromosome 8 BAC array comparative genomic hybridization and expression analysis identify amplification and overexpression of TRMT12 in breast cancer. Genes Chromosomes Cancer. 2007;46:694-707.
41. Lim DJ, Rubenstein AE, Evans DG, et al. Advances in neurofibromatosis 2 (NF2): a workshop report. J Neurogenet. 2000;14:63-106.
42. Okada T, Lopez-Lago M, Giancotti FG. Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol. 2005;171:361-371.
43. McLaughlin RW, De Stigter JK, Sikkink LA, Baden EM, Ramirez-Alvarado M. The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light-chain protein. Protein Sci. 2006;15:1710-1722.
44. Raman B, Chatani E, Kihara M, et al. Critical balance of electrostatic and hydrophobic interactions is required for beta 2-microglobulin amyloid fibril growth and stability. Biochemistry. 2005;44:1288-1299.
45. Ramirez-Alvarado M, Cocco MJ, Regan L. Mutations in the B1 domain of protein G that delay the onset of amyloid fibril formation in vitro. Protein Sci. 2003;12:567-576.
46. Ramirez-Alvarado M, Merkel JS, Regan L. Asystematic exploration of the influence of the protein stability on amyloid fibril formation in vitro. Proc Natl Acad Sci U S A. 2000;97:8979-8984.
47. Gertz MA, Lacy MQ, Dispenzieri A. Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev. 2004; 18:17-37.
48. Abraham RS, Geyer SM, Price-Troska TL, et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003;101:3801-3808.
49. Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood. 2001;98:714-720.
50. Solomon A, Frangione B, Franklin EC. Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda). J Clin Invest. 1982;70:453-460.
51. Ghiso J, Solomon A, Frangione B. Association of human lambda light chain V/J/C segments: serologic analysis and primary structure of the lambda VI Bence Jones protein THO. J Immunol. 1986; 136:716-719.
52. Qin Z, Hu D, Zhu M, Fink AL. Structural characterization of the partially folded intermediates of an immunoglobulin light chain leading to amyloid fibrillation and amorphous aggregation. Biochemistry. 2007;46:3521-3531.
53. Wall JS, Gupta V, Wilkerson M, et al. Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vlambda6 proteins. J Mol Recognit. 2004;17:323-331.
54. Taylor KL, Cheng N, Williams RW, Steven AC, Wickner RB. Prion domain initiation of amyloid formation in vitro from native Ure2p. Science. 1999;283:1339-1343.
55. Glenner GG, Ein D, Eanes ED, Bladen HA, Terry W, Page DL. Greation of "amyloid" fibrils from Bence Jones proteins in vitro. Science. 1971; 174: 712-714.
56. Kjeldsberg CR, Eyre HJ, Totzke H. Evidence for intracellular amyloid formation in myeloma. Blood. 1977;50:493-504.
57. Suzuki I, Takahashi M, Itoh S. Ultrastructural study of human myeloma cells in relation to its function. J Clin Pathol. 1970;23:339-350.
58. Zucker-Franklin D, Franklin EC. Intracellular localization of human amyloid by fluorescence and electron microscopy. Am J Pathol. 1970;59:23-41.
59. Demeule B, Gurny R, Arvinte T Where disease pathogenesis meets protein formulation: renal deposition of immunoglobulin aggregates. Eur J Pharm Biopharm. 2006;62:121-130.
60. Carrasco DR, Tonon G, Huang Y, et al. Highresolution genomic profiles define distinct clinicopathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006;9:313-325.
61. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12:131-144.
62. Largo C, Alvarez S, Saez B, et al. Identification of overexpressed genes infrequently gained/amplified chromosome regions in multiple myeloma. Haematologica. 2006;91:184-191.
63. Hanamura I, lida S, Akano Y, et al. Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. Jpn J Cancer Res. 2001;92:638-644.
64. Kataoka K, Fujiwara KT, Noda M, Nishizawa M. MafB, a new Maf family transcription activator that can associate with Maf and Fos but not with Jun. Mol Cell Biol. 1994;14:7581-7591.
65. Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, Sacchettini JC. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol. 2000;7:312-321.
66. Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A. 1996;93:15051-15056.